Business
Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for
About this update from Curis, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced a poster presentation with new preclinical data for CI-8993, a first-in-class monoclonal antibody VISTA antagonist, at the Society for Immunotherapy of Cancer's 36th Annual Meeting.\n\n \n \n \n \n \n \n\n \nThe investigational product CI-8993 is a fully human IgG1K monoclonal antibody that binds specifically to this immune checkpoint molecule. To assist in determining the pharmacokinetics and biodistribution of CI-8993 in patients, Dr. Fiona Scott, in collaboration with Prof. Andrew Scott, both of the Olivia Newton-John Cancer Research Institute, conducted a study aimed to develop a Zirconium-89 (89Zr)-labelled CI-8993 for PET (positron-emission tomography) imaging and quantitation, and to validate in preclinical models prior to a planned human trial.\nBiodistribution was assessed by image analyses, and tissue counting, with IHC analyses performed to verify VISTA antigen expression. The abstract concluded that the study has validated 89Zr-Df-CI-8993 for specific binding to huVISTA in-vivo. A clinical trial of 89Zr-Df-CI-8993 is planned in solid tumor patients.\n\"We are pleased to work with the Olivia Newton-John Cancer Research Institute to further our understanding CI-8993 and VISTA biology. These findings further expand the strong foundation of preclinical data supporting CI-8993 and bring us one step closer to delivering on the promise of anti-VISTA therapy for patients with solid tumors,\" said James Dentzer, President and Chief Executive Officer of Curis.\nDetails of the presentation are as follows:Title: Preclinical evaluation of anti-VISTA antibody CI-8993 in a syngeneic huVISTA-KI modelPresenting Author: Andrew M. Scott, MD Olivia Newton-John Cancer Research Institute, Tumour Targeting Laboratory, Melbourne, VIC, AustraliaAbstract Number: 324Abstracts will be available Tuesday, November 9, 2021, at 8:00 a.m.Virtual ePoster presentations will be available Friday, November 12, 2021, at 7:00 a.m.\nAdditional meeting information can be found on the SITC website at:https://www.sitcancer.org/2021/home.\nThe presentations will also be available under \"Posters and Presentations\" in the Pipeline: CI-8993 section of the Company's we...